Skip to main content

Table 3 Lung function (COPD-6™, spirometry) according to the presence and severity of COPD according to GOLD stages

From: Diagnostic accuracy of a pocket screening spirometer in diagnosing chronic obstructive pulmonary disease in general practice: a cross sectional validation study using tertiary care as a reference

 

Lung function

All

Non-COPD

COPD

GOLD 1

COPD

GOLD 2

Statistics

(N = 227)

(n = 184)

(n = 24)

(n = 19)

COPD-6™

FEV1 (% predicted)

94.3 ± 15.6

97.6 ± 13.3

90.9 ± 13.0

67.5 ± 12.2

F = 46.27 P < 0.001

FEV6 (% predicted)

93.9 ± 16.2

96.0 ± 15.3

94.7 ± 14.9

74.5 ± 13.7

F = 17.27 P < 0.001

FEV1/FEV6 (%)

0.845 ± 0.085

0.864 ± 0.071

0.781 ± 0.083

0.757 ± 0.117

F = 25.84 P < 0.001

Lung age (yrs)

60.7 ± 13.9

57.7 ± 11.1

64.0 ± 11.1

84.6 ± 15.7

F = 48.07 P < 0.001

Spirometry

FEV1 (% predicted)

97.9 ± 15.3

101.5 ± 12.9

92.9 ± 10.2

71.1 ± 12.7

F = 51.50 P < 0.001

FVC (% predicted)

109.3 ± 17.0

110.8 ± 16.7

112.7 ± 11.8

91.1 ± 16.2

F = 13.29 P < 0.001

FEV1/FVC (%)

0.742 ± 0.073

0.761 ± 0.060

0.665 ± 0.055

0.650 ± 0.073

F = 49.14 P < 0.001

ΔFEV1 (%)

1.39 ± 4.00

1.40 ± 3.79

2.92 ± 4.25

−0.93 ± 7.68

F = 3.011 P = 0.051

  1. Data for all variables is presented as mean ± standard deviation; FEV 1 forced expiratory volume in 1 s, FEV 6 forced expiratory volume in 6 s, FVC forced expiratory volume, ΔFEV 1 post-bronchodilator change in FEV1 (measured 20 min after inhalation of 400 μg of salbutamol), F – result of ANOVA for between group comparisons